Werewolf Therapeutics

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of cancer immunotherapies. Incorporated in 2017 by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin, the company was seeded and incubated by venture capital firms MPM Capital and Longwood Fund. Dr. Hicklin, the President and CEO, brings extensive experience in oncology drug discovery, having previously founded and led Potenza Therapeutics and CoStim Pharmaceuticals. His background includes significant roles at Merck Research Laboratories, where he was involved with the development of Keytruda, and ImClone Systems, supporting the approval of Erbitux. Co-founder Luke Evnin is a Managing Director at MPM Capital with a long history of founding and investing in successful biotech companies.

The company's core business revolves around its proprietary PREDATOR® platform, engineered to create conditionally activated therapeutics. These molecules, called INDUKINEs™, are designed to be administered systemically in an inactive state and become fully active only within the tumor microenvironment (TME). This approach aims to solve a critical problem in immunotherapy: the severe toxicity associated with systemically active treatments, thereby improving the therapeutic window. The business model is typical for a clinical-stage biotech, currently generating no revenue from product sales and relying on capital from investors and strategic partnerships to fund its extensive research and development. A key milestone was a 2022 licensing deal with Jazz Pharmaceuticals for WTX-613, which provided a $15 million upfront payment.

Werewolf Therapeutics went public in May 2021 with an IPO that raised approximately $120 million to advance its pipeline. The company's lead product candidates are WTX-124 and WTX-330. WTX-124 is a conditionally activated Interleukin-2 (IL-2) INDUKINE molecule being evaluated in Phase 1/1b clinical trials, both as a monotherapy and in combination with the checkpoint inhibitor pembrolizumab for various solid tumors. Early results have shown objective clinical responses, including a confirmed complete response, in heavily pretreated patients. WTX-330 is a conditionally activated Interleukin-12 (IL-12) INDUKINE designed for tumors resistant to immunotherapy. It is being evaluated in a Phase 1 trial for advanced or metastatic solid tumors or non-Hodgkin lymphoma. The company is also expanding its PREDATOR® platform to develop INDUCER™ molecules, a new class of T cell engagers, and is exploring applications for inflammatory diseases like IBD with its WTX-921 candidate.

As a pre-revenue entity, the company's financials are characterized by significant R&D expenditures, which were $56.4 million for the full year 2024. Net losses were reported at $70.5 million for the same period. As of September 30, 2025, the company reported $65.7 million in cash and cash equivalents, which is projected to fund operations into the fourth quarter of 2026. The company's future is closely tied to upcoming clinical data readouts and its ability to navigate the regulatory pathway toward commercialization.

Keywords: immuno-oncology, PREDATOR platform, INDUKINE, conditionally activated therapeutics, WTX-124, WTX-330, interleukin-2, IL-2, interleukin-12, IL-12, tumor microenvironment, cancer therapy, clinical-stage biopharmaceutical, Daniel J. Hicklin, MPM Capital, solid tumors, immunotherapy, checkpoint inhibitors, T cell engager, JZP-898, WTX-613, HOWL, oncology drug development, cytokine therapies, protein engineering, tumor-selective activation, WTX-712, IL-21, WTX-518, IL-18, inflammatory bowel disease